Advances in artificial intelligence: ChatGPT and the implications for medical writing

Dec 23, 2022

A picture of a humanoid robot using a computer. Generated using DALL-E artificial intelligence
Written by Dom Partridge, Medical Writer

As artificial intelligence (AI) technology continues to advance, natural language processing (NLP) models like ChatGPT have gained a lot of attention for their ability to generate human-like text. However, while ChatGPT and other NLP models may be impressive, they are not yet capable of truly replicating human intelligence and should not be mistaken for such.

NLP is the ability of a computer programme to understand, interpret, and generate human language. It involves using algorithms and machine learning techniques to analyse and process natural language data, such as speech and text. This technology is used in a variety of applications, including language translation, voice recognition, and text summarisation. A common use for NLP that most writers use are spelling and grammar checkers, such as Microsoft® Word’s Editor or Grammarly. The NLP algorithms used by these checkers analyse text and compare it with a pre-existing database of correctly spelled words and grammatically correct sentences. When an error is detected, the checker suggests a correction or supplies a warning to the user. This allows the user to quickly find and fix errors in their writing, improving the overall quality and clarity of their text.

However, recent advances in AI, such as the release of ChatGPT and DALL-E (used to create the image accompanying this blog), have opened new possibilities for medical writers.

For example, it is possible for AI models, including ChatGPT, to generate value messaging from uploaded documents and a simple command prompt. Value messaging refers to the core messages and key points that a company wishes to communicate to its audience. These messages are typically used to highlight the benefits and advantages of a product, service, or idea. Using natural language processing algorithms, AI models can analyse the key features and benefits of a product or service, and then generate compelling value messages that effectively communicate these key points to the audience. However, although AI can generate text that is grammatically correct with a coherent flow, it cannot yet replicate the nuance and understanding of a human writer. Additionally, AI currently lacks the ability to create infographics from text, although it can pull out key points.

Another example is the ability of AI models to summarise technical documents quickly and efficiently. This has the potential to speed up a number of tasks that medical writers perform, such as producing clinical study reports, searching for specific data points, and researching new disease areas. However, the currently available models cannot yet actively search the internet for this information, and therefore the text to be summarised needs to be uploaded, which may have implications for confidentiality.

In conclusion, while ChatGPT and other AI systems may be able to perform some tasks that have traditionally been done by people, they are not currently capable of truly replicating human intelligence and creativity. These systems are only as good as the data they are trained on, and lack the ability for original thought and critical thinking that humans possess. For this reason, it may be best to treat AI models as a useful tool rather than relying on them completely.

If you are interested in finding out more about our medical writing or value communications services, please contact the Market Access and Value Communication team at Source Health Economics, an independent consultancy specialising in evidence generation, health economics, and communication.


More Insights

HTA monthly – April updates

HTA monthly – April updates

Written by Kiera Lander & Oliver Burn   1 - A NICE modular update: adopting the EQ‑5D‑5L UK value set   What is changing (methods update) The National Institute for Health and Care Excellence (NICE) is consulting ... Read more

HTA quarterly update

HTA quarterly update

Written by Ben Clark, Paloma Charlesworth, and Kiera Lander   This quarterly update highlights recent and upcoming developments shaping the health technology assessment (HTA) environment across Europe, with a particular focus on rare ... Read more

Accelerating hope? Optimising rare disease MHRA/FDA approval pathways and access strategy considerations

Accelerating hope? Optimising rare disease MHRA/FDA approval pathways and access strategy considerations

Written by Jo Wallis, Head of Commercialisation and Pricing Strategy   The recent developments put forward by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Food and Drug Administration (FDA) to streamline the ... Read more

The role of orphan drug designations in driving research and innovation for rare diseases

The role of orphan drug designations in driving research and innovation for rare diseases

Written by Emma Bartram, Associate Systematic Review Analyst   A rare disease is one that affects fewer than 1 in 2,000 individuals, and yet 3.5–5.9% of people will experience a rare disease over the course of their lifetime (1,2). ... Read more